SCAFFOLD PROTEIN DRIVERS
SCAFFOLD PROTEIN TRIAL

TP-3654, the company's proprietary investigational oral inhibitor of PIM kinases, was granted Orphan Drug Designation for the treatment of myelofibrosis ( NCT04176198) as well as DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor, was also granted Orphan Drug Designation for the treatment of brain cancer ( NCT05023551). This is the third recently announced Orphan Drug Designation from SMP Oncology. To learn more about the study and eligibility for enrollment, visit ( NCT04988555).

SCAFFOLD PROTEIN TRIAL

'We're encouraged by preclinical evidence showing that blocking the menin-MLL interaction may stop the development of leukemia and restore normal terminal differentiation in MLL rearranged and NPM1-mutant malignant myeloid cells.' 2,6ĭSP-5336 is currently being evaluated in a Phase 1/2 clinical trial to evaluate the safety and efficacy of DSP-5336 in patients with Relapsed/Refractory AML/ ALL with or without MLL Rearrangement or NPM1 Mutation, which is being conducted in the United States and Japan. Shah, M.D., Chief Medical Officer of Sumitomo Pharma Oncology, Inc. DSP-5336 is a small molecule that blocks the MLL-menin partnership which inhibits normal differentiation and promotes leukemia growth.' 2-5 detailed Jatin J.

SCAFFOLD PROTEIN DRIVERS

'MLL gene rearrangements and nucleophosmin 1 (NPM1) mutations are potent drivers of leukemia growth, and menin is a necessary copilot. AML swiftly moves from the bone marrow into your bloodstream and can even involve other parts of your body. However, in people with AML, the bone marrow makes abnormal cancerous white blood cells called myeloid blasts. Bone marrow typically produces white blood cells, red blood cells and platelets. AML is a blood cancer that starts in bone marrow. The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.

'We are excited to contribute to the advancement of research in this hematologic malignancy.' Andrews, CEO and Global Head of Oncology, Sumitomo Pharma Oncology, Inc. 'We are pleased to have received this designation for DSP-5336 which reinforces the need to identify novel therapeutic options to improve outcomes for patients with AML,' said Patricia S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute myeloid leukemia (AML). 3, 2022 /PRNewswire/ - Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S.

Scaffold protein